Stryker Corporation
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Kevin A. Lobo
- Full Time Employees
- 56,000
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 1941 Stryker Way Portage MI United States 49002
- IPO Date
- Mar 17, 1980
- CIK
- 0000310764
- Website
- stryker.com
- Similar Companies
- Business
- Stryker Corporation (NYSE: SYK) develops, manufactures, and markets medical technologies, including orthopedic implants and instruments; surgical equipment and navigation systems; endoscopic and communications products; and patient handling and emergency medical equipment. The company offers its Mako robotic-arm assisted surgery platform for orthopedic procedures; Triathlon and Trident hip and knee systems; Gamma3 and T2 intramedullary nailing systems; and Ceros and Variax distal fixation systems, among other specialized devices for joint reconstruction, trauma and extremities, and spine care. Stryker provides interventional devices, including embolic products and guidewires, along with neurotechnology and spine products such as Vizor vision systems and SurgiCount safety sponges; it also delivers solutions for operating room integration and capital equipment. Founded in 1941 and headquartered in Kalamazoo, Michigan, the company operates globally across the Americas, Europe, Asia-Pacific, and other regions, serving hospitals, ambulatory surgery centers, and healthcare providers in the medtech industry. In recent developments, Stryker completed the acquisition of Artelon AB in September 2024, enhancing its sports medicine portfolio with advanced biomaterials for soft tissue regeneration. The company also acquired Wright Medical Group N.V. in 2022, bolstering its extremity reconstruction offerings, and continues to expand through strategic investments, including a new manufacturing facility in Ireland to support European growth. Additionally, Stryker launched the next-generation Mako Total Knee 2.0 application and advanced its Blue Seal bipolar sealer technology, reflecting ongoing innovation in robotics and surgical efficiency amid robust demand in orthopedics and neurotechnology segments.
Company News
3 Medical Device Stocks That Keep Raising Dividends. One Just Hit 55 Years
Diamond Hill Large Cap Fund Q3 2026 Portfolio Update
3,649 Stryker Corporation $SYK Shares Sold by Boston Trust Walden Corp
Stryker Corporation $SYK Stock Bought by International Assets Investment Management LLC
SYK Stock Skids as Q3 Earnings and Sales Miss & 2026 Outlook Cut
Stryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSS
SYK Q3 Earnings Call Highlights Softer Demand and Revised Outlook
What Stryker (SYK) Said on Its Q3 Earnings Call
Stryker Analysts Cut Their Forecasts Following Downbeat Q3 Earnings
Stryker's Guidance Cut Rattles Investors: What It Really Says About 2027
Stryker Corporation (SYK) Q3 2026 Earnings Call Transcript
Stryker (SYK) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Stryker (SYK) Q3 Earnings and Revenues Lag Estimates
Stryker Q3 2026 Earnings Call Transcript
Stryker reports third quarter 2026 operating results
SYK Q3 Earnings: Can Recovery Momentum Offset Operational Headwinds?
Stryker to participate in the 2026 Jefferies Global Healthcare Conference
It's Too Soon To Upgrade Stryker Corporation
Countdown to Stryker (SYK) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Stryker completes acquisition of ZuriMED to enhance its shoulder offering